Company Encyclopedia
View More
name
Champions Oncology
CSBR.US
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies.
770.48 B
CSBR.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
Life Sciences Tools and ServicesIndustry
Industry Ranking11/60
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE185.89%A
    • Profit Margin5.19%C
    • Gross Margin42.87%B
  • Growth ScoreB
    • Revenue YoY10.11%B
    • Net Profit YoY186.90%A
    • Total Assets YoY22.51%A
    • Net Assets YoY1165.66%A
  • Cash ScoreB
    • Cash Flow Margin1926.76%A
    • OCF YoY10.11%B
  • Operating ScoreA
    • Turnover2.05A
  • Debt ScoreE
    • Gearing Ratio88.42%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Craig-Hallum Sticks to Their Buy Rating for Champions Oncology (CSBR)

    Hewitt covers the Healthcare sector, focusing on stocks such as Repligen, Alpha Teknova, and Apyx Medical. According to TipRanks, Hewitt has an average return of 0.0% and a 43.22% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Champions Oncology.

    Tip Ranks·
    US
    CSBR
    +1.84%
    Tip Ranks·
    US
    CSBR
    +1.84%

    Champions Oncology Holds Annual Stockholders Meeting

    Champions Oncology (CSBR) held its Annual Stockholders Meeting on October 16, 2025, where seven director nominees were elected, and EisnerAmper LLP was ratified as the independent auditor. A non-binding advisory resolution on executive compensation received shareholder support. Analysts rate CSBR stock as a Hold with a $6.50 price target, reflecting a mixed outlook due to improved profitability but high leverage and declining cash flow. The stock shows a bearish trend and is considered overvalued, despite cautious optimism for future growth.

    Tip Ranks·
    US
    CSBR
    +1.84%
    Tip Ranks·
    US
    CSBR
    +1.84%

    Champions Oncology Earnings Call: Cautious Optimism Amid Challenges

    Champions Oncology's recent earnings call revealed cautious optimism amid ongoing challenges. The company reported a revenue rebound to $14 million in Q1, but year-over-year revenue remained flat. Despite an operating loss of $0.5 million and a decline in gross margins from 50% to 43%, Champions maintains a strong cash position of $10.3 million and no debt. The expansion of its data platform and radiopharmaceutical services is expected to drive future growth. Looking ahead, the company anticipates sequential revenue growth and margin expansion in fiscal 2026.

    Tip Ranks·
    US
    CSBR
    +1.84%
    Tip Ranks·
    US
    CSBR
    +1.84%

    Champions Oncology | 8-K: FY2026 Q1 Revenue: USD 14 M

    LB filings·
    US
    CSBR
    +1.84%
    LB filings·
    US
    CSBR
    +1.84%

    Champions Oncology | 10-Q: FY2026 Q1 Revenue: USD 14 M

    LB filings·
    US
    CSBR
    +1.84%
    LB filings·
    US
    CSBR
    +1.84%
    © 2025 Longbridge｜Disclaimer